Terrance Mcguire Sells 86,545 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 86,545 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $0.48, for a total transaction of $41,541.60. Following the sale, the director now owns 3,170,231 shares in the company, valued at $1,521,710.88. The trade was a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The stock was sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $0.48 on Friday. The firm has a market cap of $57.42 million, a P/E ratio of -0.24 and a beta of 0.53. Invivyd, Inc. has a 1 year low of $0.40 and a 1 year high of $5.20. The firm’s 50 day moving average price is $0.70 and its 200 day moving average price is $0.95.

Institutional Investors Weigh In On Invivyd

Hedge funds have recently made changes to their positions in the business. Duquesne Family Office LLC acquired a new position in Invivyd in the second quarter valued at $629,000. Acadian Asset Management LLC grew its holdings in Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after buying an additional 474,301 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in shares of Invivyd during the 2nd quarter valued at about $86,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after acquiring an additional 53,499 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after acquiring an additional 82,164 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Morgan Stanley cut their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. HC Wainwright lowered their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Thursday, November 21st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.